Adherex and National Cancer Institute to Collaborate

Adherex Technologies, a biopharmaceutical company with a broad portfolio of oncology products under development, announced that the Drug Development Group of the U.S. National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis has approved a Level III collaboration for the clinical development of the company's lead biotechnology compound ADH-1, also known as Exherin, provided additional preclinical studies be conducted.

Yahoo News (http://biz.yahoo.com/ccn/050311/b7289a3f5a2cf7768e88bb20a72fa9e7_1.html)